Table 4.
Current phase I/II survivin vaccine clinical trials
| Conditions | Intervention | PI/sponsor/NCT identification | Phase |
|---|---|---|---|
| Malignant melanoma, pancreatic cancer, colon cancer, cervical cancer | Survivin peptide vaccine | J. C Becker, MD, PhD/Julius-Maximilians University/NCT00108875 | I/II |
| Breast neoplasm, breast cancer, cancer of the breast, carcinoma, ductal | hTERT/Survivin multi-peptide vaccine | S. Domchek, MD & K. Fox, MD/ University of Pennsylvania/ NCT00573495 | I |
| Melanoma (skin) | Melan-A, MAGE-3, and Survivin RNA-transfected DC vaccine | G. Schuler, MD/Dermatologische Klinik MIT Poliklinik-Universitaetsklinikum Erlangen/NCT00074230 | I/II |
| Multiple myeloma and plasma cell neoplasm | Survivin peptide vaccine | A. Rapoport, MD/University of Maryland Greenebaum Cancer Center; National Cancer Institute (NCI)/NCT00499577 | I/II |
| Advanced renal cell carcinoma | Survivin and telomerase peptide-pulsed dendritic cells | I. Svane, MD, PhD/Herlev Hospital/NCT00197860 | I/II |
| Advanced melanoma | p53, survivin, and telomerase peptide-pulsed dendritic cells | I. Svane, MD, PhD/Herlev Hospital/NCT00197912 | I/II |
Information collected from http://www.clinicaltrials.gov; search term: survivin vaccine